Seek Labs

Seek Labs is a TechBio company developing a new class of programmable CRISPR-based antivirals and diagnostics for high-impact infectious diseases. The company integrates machine learning–driven target discovery with modular therapeutic and diagnostic platforms to dramatically compress development timelines and enable rapid response to pandemic, zoonotic, and neglected diseases.

At the core of Seek Labs is BioSeeker™, a proprietary machine learning engine that analyzes large-scale pathogen genomic data to identify conserved, disease-driving targets suitable for therapeutic ablation or diagnostic detection. BioSeeker automates target discovery, prioritization, and optimization, reducing early-stage discovery timelines from years to months and generating partner-ready programs across human and veterinary infectious diseases.

BioSeeker directly programs Seek Labs’ Programmable Target Ablation Platform (PTAP), a CRISPR-based therapeutic system designed to irreversibly disrupt essential pathogen genetic sequences. PTAP enables precise, multiplexed targeting to halt replication, reduce resistance risk, and improve durability across diverse viral families. The platform supports rapid program creation, scalable licensing, and deployment across both commercial and public health settings.

PTAP delivers compressed development timelines, typically targeting 12 months or less from discovery to in vivo validation, alongside substantial reductions in early R&D cost. The platform supports pathogen-specific and pan-pathogen approaches and is designed for repeatability across emerging and endemic threats.

Seek Labs has validated PTAP in vivo through its African Swine Fever Virus program. In 2024, the company demonstrated extended survival and reduced viral load in infected pigs, validating both biological efficacy and platform speed in a disease with no approved treatment. African Swine Fever has caused over $196B in global economic losses and remains a major food security threat. The ASFV program is now under active commercialization, establishing Seek Labs’ first path to market and validating a scalable business model for programmable CRISPR therapeutics.

To date, Seek Labs has raised $19.25M and built a cross-functional team spanning machine learning, molecular biology, translational research, and regulatory strategy. The company is actively advancing commercial partnerships, government engagements, and product readiness across human and animal health as it enters its next phase of growth.